Litcius/Paper detail

798TiP Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer

Michiel S. van der Heijden, Shilpa Gupta, Matt D. Galsky, Christina Louise Derleth, Joyce Steinberg, Ritesh Kataria, Thomas Powles

2020Annals of Oncology21 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePembrolizumabCarboplatinInternal medicineGemcitabineOncologyAtezolizumabChemotherapyMetastatic Urothelial CarcinomaCisplatinDurvalumabPhases of clinical researchCancerImmunotherapyBladder cancerUrothelial carcinomaBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesCancer Immunotherapy and Biomarkers
798TiP Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer | Litcius